Is MiMedx Group, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for MiMedx Group, Inc. moved from attractive to fair. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 24, an EV to EBIT of 16.13, and an EV to EBITDA of 14.64. In comparison to peers, LeMaitre Vascular, Inc. has a higher P/E ratio of 49.77, while Alphatec Holdings, Inc. shows a negative P/E, indicating it is in a risky position.
Despite the fair valuation, MiMedx has shown strong performance in the short term, with a 1-week return of 13.17% compared to the S&P 500's 0.71%, though it has underperformed year-to-date with a return of -20.48% against the S&P 500's 16.30%. Overall, MiMedx Group, Inc. is currently fairly valued within its industry context.